{"commentary":{"count":11,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":4,"podcast":4,"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05059236\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"ARASEC","nct_id":"NCT05059236","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=arasec-nct05059236. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"ARASEC","arms":[{"description":"Participants will receive darolutamide plus ADT in the ARASEC treatment arm. The control arm for the study will be derived from the participants treated with ADT alone in the CHAARTED trial using a matching approach","label":"Darolutamide+ADT","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-06-15","type":"ACTUAL"},"conditions":["Metastatic Hormone-sensitive Prostate Cancer"],"enrollment":{"count":223,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Darolutamide (BAY1841788, Nubeqa)","type":"DRUG"},{"name":"ADT","type":"OTHER"}],"last_update":"2026-09-15","lead_sponsor":"Bayer","official_title":"Open-label Study of Androgen Receptor Inhibition With dArolutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Men With Metastatic Hormone-Sensitive Prostate Cancer Using an External Control Arm","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2025-05-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"From start of treatment to the date when approximately 161 PFS events were observed across the ARASEC cohort and the matched controls, approximately 40 months"}],"references":[{"citation":"McKay RR, Ross AE, Preston MA, Gregg JR, Salami SS, Littleton N, Constantinovici N, Srinivasan S, Verholen F, Shore ND. Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients. Future Oncol. 2025 May;21(11):1365-1375. doi: 10.1080/14796694.2025.2482360. Epub 2025 Apr 1.","pmid":"40165634","type":"DERIVED"}],"start_date":{"date":"2021-11-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.","url":"https://clinicaltrials.gov/study/NCT05059236"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/arasec-nct05059236"}